Key result
New bedside platelet function tests offer rapid turnaround times compared to traditional turbidimetric aggregometry for monitoring antiplatelet therapy in patients with coronary disease.
Why the study?
What are the performance characteristics and clinical utility of rapid bedside platelet function tests in patients with coronary disease on antiplatelet therapy?
What are the performance characteristics and clinical utility of rapid bedside platelet function tests in patients with coronary disease on antiplatelet therapy?
Answers are grounded in this paper and cite their sources.
Rapid bedside platelet function tests may offer a practical alternative to traditional cumbersome methods for monitoring antiplatelet therapy in patients with coronary disease.
The role of the platelet in the pathogenesis of acute coronary syndromes is clearly established. In addition, the beneficial effects of oral and intravenous platelet inhibitor therapies were demonstrated in multiple, large, randomized clinical trials. However, despite these advances, current antiplatelet therapy fails to prevent coronary events in a substantial proportion of patients. One possible explanation for this phenomenon is that antiplatelet medications are administered without monitoring of the response to therapy. For example, oral antiplatelet therapy is administered as a standard dose for all patients, while intravenous inhibitors of the platelet glycoprotein (GP) IIb/IIIa receptor are dosed based on patient body weight. A major limitation of measuring platelet function has been that no practical test exists. The historic gold standard, bleeding time, was a very crude measure of platelet function with limited clinical utility. The current "gold standard," turbidimetric aggregometery, requires a central laboratory and is cumbersome to perform. Fortunately, a number of new tests with rapid turnaround time can be performed at the patient's bedside. This article discusses the details regarding the performance, advantages, disadvantages, and available data related to clinical use of each test in populations with coronary disease and patients treated with antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Thompson et al. (2002) conducted a review in Coronary disease. Platelet function tests was evaluated. New bedside platelet function tests offer rapid turnaround times compared to traditional turbidimetric aggregometry for monitoring antiplatelet therapy in patients with coronary disease.
Synapse has enriched 10 related papers. Consider them for comparative context: